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Abstract
The androgen receptor (AR) is required for prostate cancer (PCa) survival and progression, and 
ablation of AR activity is the first line of therapeutic intervention for disseminated disease. While 
initially effective, recurrent tumors ultimately arise for which there is no durable cure. Despite the 
dependence of PCa on AR activity throughout the course of disease, delineation of the AR-
dependent transcriptional network that governs disease progression remains elusive, and the 
function of AR in mitotically active cells is not well understood. Analyzing AR activity as a 
function of cell cycle revealed an unexpected and highly expanded repertoire of AR-regulated 
gene networks in actively cycling cells. New AR functions segregated into two major clusters: 
those that are specific to cycling cells and retained throughout the mitotic cell cycle (“Cell Cycle 
Common”), versus those that were specifically enriched in a subset of cell cycle phases (“Phase 
Restricted”). Further analyses identified previously unrecognized AR functions in major pathways 
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associated with clinical PCa progression. Illustrating the impact of these unmasked AR-driven 
pathways, dihydroceramide-desaturase 1 (DEGS1) was identified as an AR regulated gene in 
mitotically active cells that promoted pro-metastatic phenotypes, and in advanced PCa proved to 
be highly associated with development of metastases, recurrence after therapeutic intervention, 
and reduced overall survival. Taken together, these findings delineate AR function in mitotically 
active tumor cells, thus providing critical insight into the molecular basis by which AR promotes 
development of lethal PCa and nominate new avenues for therapeutic intervention.
Introduction
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancy in the 
USA, and the second most lethal form of cancer (1). While localized disease is readily 
treatable through surgery and/or radiation, there is no curative intervention for advanced 
PCa. Advanced PCa typically remains reliant on androgen receptor (AR) signaling 
throughout disease progression (2, 3). As a hormone nuclear receptor, AR requires androgen 
(testosterone or dihydrotestestone, DHT) binding for activation. Once active, AR binds DNA 
and initiates transcriptional programs required for proliferation and survival, however the 
mechanisms governing these events have remained largely elusive. By contrast, the 
mechanism by which AR regulates proteases important for prostate function (e.g. Prostate 
Specific Antigen, PSA, encoded by KLK3), are well known, and PSA is used clinically to 
monitor tumor development and progression (4). Given the exquisite dependence of PCa on 
AR function, therapy for disseminated disease suppresses AR signaling, achieved by 
ablation of circulating ligand (androgen deprivation therapy, ADT), often used in 
combination with direct AR antagonists (2, 5). While initially efficacious, these regimens 
ultimately fail and castration resistant prostate cancer (CRPC) develops due to reactivation 
of the AR signaling axis (3, 6, 7). At present, there remain no durable means to manage 
recurrent AR activity and treat CRPC; as such developing understanding of AR function and 
mechanisms to target downstream processes represents a primary focus in the field.
Despite the importance of AR in driving PCa progression, the specific gene networks 
controlled by AR to induce advanced tumor phenotypes are not well understood. Recent 
studies revealed a role for AR in regulating PCa cell metabolism particularly as involved in 
glycolysis and anabolism flux, thereby supporting tumor cell growth (8, 9). Additionally, AR 
can indirectly modulate cell cycle progression via mTOR-dependent pathways that lead to 
Cyclin D1 accumulation, consequent activation of cyclin dependent kinase 4 (CDK4) and 
phosphorylation/inactivation of the RB tumor suppressor, and subsequent G1-S checkpoint 
transition (10). These observations provide clues to the biochemical framework for how AR 
promotes tumor cell growth, but the molecular basis for AR-dependent phenotypes 
associated with cell survival, cell migration, and metastasis remains largely unsolved. It is 
notable that genome wide analyses of AR activity have been performed in cells 
synchronized in G0 through steroid deprivation, leaving unresolved the role of AR in 
mitotically active cells (9, 11).
Studies herein reveal that AR induces differential transcriptional networks in mitotically 
active cells, unmasking critical new insight into AR function. Molecular dissection 
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demonstrated that networks specific to actively cycling cells can be subdivided into those 
that are common to all active phases of the cell cycle, versus those that are specifically 
enriched in distinct cell cycle phases. Networks identified were strongly associated with 
novel AR cistromes through genome-wide binding analyses, demonstrating the unexpected 
finding that AR function is significantly expanded in cells committed to the mitotic cell 
cycle, and that AR function is sensitive to cell cycle position. Functional analyses unveiled 
novel mechanisms through which AR likely promotes pro-tumorigenic phenotypes including 
cell migration and tumor metastases. Of particular significance was the discovery of 
DEGS1, a desaturase involved primarily in the formation of ceramide, as a key target 
through which AR promotes pro-metastatic phenotypes. Analyses in human tumor samples 
further identified DEGS1 as strongly associated with disease progression and poor outcome, 
outperforming current biomarkers of aggressive disease. Taken together, the studies herein 
demonstrate that AR signaling is widely expanded in mitotically active cells, and promotes 
pro-tumorigenic networks underpinning cancer progression.
Results
Androgens Induce Distinct Gene Expression Programs in Cycling Cells
Despite the known ability of AR to promote PCa growth and progression, the molecular 
basis of AR function remains incompletely understood. As the majority of genome-wide 
analyses have been performed in cells that have exited the cell cycle via steroid deprivation 
prior to hormone stimulation, it was posited that AR functions supporting lethal tumor 
phenotypes may be uncovered by assessing AR activity in mitotically active cells. To 
explore this, human PCa models were utilized to discretely assess cell cycle-dependent 
effects of androgen and downstream cellular consequences. A baseline for AR activity in 
resting cells deprived of androgen was established using hormone therapy sensitive (HTS) 
PCa cells synchronized in G0 through steroid starvation (Fig 1A). In parallel, cells cultured 
in steroid replete conditions were enriched for distinct phases of cell cycle and subsequently 
subjected to a 3-hr pulse of DHT. Cells were enriched prior to DHT stimulation in early G1 
(through use of a CDK4 inhibitor, 87.2% G1 phase), late G1 (via CDK2 suppression, 72.3% 
G1 phase), in early S (by DNA polymerase inactivation, 42.2% S phase), in mid-S phase 
(through suppression of ribonucleotide reductase, 34.5% S phase), and G2/M (through 
release from S-phase into nocodazole, 33.5% G2/M). Robust enrichment in desired phases 
was validated through flow cytometric analyses (Fig 1A). Differentially enriched transcripts 
were identified through gene expression analyses and compared to unstimulated (G0, steroid 
deprived) cells using a stringent cutoff for both fold change (FC≥1.5) and false discovery 
rate (FDR≤10%). After applying filtering parameters, 1098 transcripts demonstrated 
differential (positive or negative) cell cycle-regulated expression compared to unstimulated 
cells in G0. To identify androgen-responsive transcriptomes specific to distinct cell cycle 
phases, genes were clustered using a center-means based approach, considering only 
expression levels in DHT stimulated samples. Clustering analysis revealed that maximum 
up-regulation occurred after cell cycle commitment in early S phase and beyond, with 
maximum down-regulation observed in late G1 phase (Fig 1B). Additionally, changes in 
gene expression were not due to appreciable changes in AR protein levels (Fig 1C top), or 
alterations in AR nuclear localization (Fig 1C bottom). Further, in order to examine whether 
McNair et al. Page 3
Oncogene. Author manuscript; available in PMC 2017 March 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
these expression changes could be mimicked through longer DHT stimulation times, genes 
altered specifically at 24 hour DHT stimulation were examined(12). Intriguingly, less than 
50% of genes changed at 24 hours were seen to undergo cell cycle regulated gene expression 
in the current study, suggesting that while longer DHT stimulation times may identify a 
subset of these targets, it is not sufficient to identify a majority of genes differentially 
regulated by cell cycle phase (Fig S1). These observations suggest that AR-cell cycle 
interplay elicits distinct alterations in AR transcriptome in mitotically active cells, dependent 
on cell cycle phase.
Gene set enrichment analysis (GSEA) identified DHT-responsive gene networks 
demonstrating cell-cycle enrichment specific to actively cycling PCa cells. Briefly, 
transcripts enriched in individual phases were systematically compared to the remaining 
datasets, resulting in identification of DHT-responsive gene networks that are up-regulated 
(Fig 1D left panel, Fig S2, Supplementary Table 1) or down-regulated (Fig 1D right panel, 
Fig S2, Supplementary Table 1) in a phase restricted manner. As expected, pathways 
previously identified as androgen regulated (e.g. androgen response and E2F hallmark 
signatures) (13–15) were up-regulated in early G1, early S, and G2/M phases (Fig 1D left). 
Both pathways were subsequently down-regulated in late G1 and late S (Fig 1D right), 
suggesting that previously reported androgen regulated pathways are cell cycle-dependent. 
Additionally, as AR has been recently shown to play an important role in DNA repair (16, 
17), it is notable that hallmark DNA repair and p53 regulated genes were up-regulated by 
DHT exclusively in S and G2/M phases, suggesting that the capacity of AR to modulate 
DNA repair is also sensitive to cell cycle position. Finally, pathways exclusively up-
regulated in late S phase include epithelial to mesenchymal transition (EMT) and 
inflammatory signaling, pathways known to promote clinical progression in human disease 
(18, 19). These observations reveal putative new downstream consequences of AR signaling 
that provide insight into the means by which this receptor modulates aggressive tumor 
phenotypes. Mechanistically, these data reveal for the first time that AR signaling elicits 
distinct transcriptional programs across the cell cycle, and harbors expanded functions in 
mitotically active cells.
The AR Cistrome is Expanded in Mitotically Active Cells
To discern the molecular basis of the observed expanded gene networks controlled by AR in 
mitotically active cells, parallel studies were performed to assess the cell cycle specific AR 
cistrome. AR binding sites (ARBSs) were found through chromatin immunoprecipitation 
followed by deep sequencing (ChIP-Seq), using standard methodology (20). Statistically 
significant ARBSs within each phase were identified using MACS peak calling algorithm 
and a rigorous cutoff (p<1e−8). As expected, DHT significantly increased AR binding 
intensity in all phases when compared to steroid deprived cells; however, there was noted 
variance in DHT-induced intensity of AR binding amongst the cell cycle phases, with G2/M 
enriched cells demonstrating the highest intensity, and late G1 and late S exhibiting the 
weakest intensity (Fig 2A), perhaps reflective of differential chromatin accessibility in early 
versus late cell cycle. Using the cis-regulatory element annotation system (CEAS, Figure 
2B), in unstimulated (G0) cells, AR bound intronic (29.2%) and distal intergenic (55.4%) 
regions, with a small fraction observed in promoter (0–3000bp from TSS, 7.2%) and 
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downstream (0–3000bp from TTS, 6.3%) regions. Comparatively, AR binding in mitotically 
active cells occurred most frequently (>95%) in intronic and distal intergenic regions, 
indicating a shift in preferential binding regions after DHT treatment and cell cycle 
activation. Additionally, binding events in early G1, early S, and G2/M contained 
comparable numbers of AR occupied sites (38,620; 41,023; and 40,884 respectively), 
whereas binding in late G1 and late S was slightly reduced (26,202 and 20,720 respectively, 
Fig 2C). These data demonstrate that AR exhibits a differential binding profile amongst 
different phases of the cell cycle, consistent with differential DHT-induced gene networks in 
mitotically active cells.
Further analyses of expanded AR binding events in mitotically active cells resulted in 
identification of two major patterns of AR binding, including occupancy at sites that are 
specific to the mitotic cell cycle but retained in all phases (deemed cell cycle common, or 
CCC) counterbalanced by occupancy events that are enriched in specific phases of the 
mitotic cell cycle (phase restricted binding, or PRB). Comparatively, 28,693 sites were 
classified as CCC pattern events, and 17,056 meeting the criteria of PRB binding events (Fig 
2C,D). In the PRB subclass, early G1, early S, and G2/M phase showed similar numbers of 
phase-restricted binding events, with late G1 phase exhibiting a marked decrease in AR 
binding events, and late S phase showing the least evidence of phase-restricted AR 
occupancy (Fig 2D). These collective observations are consistent with the identification of 
cell cycle specific AR signaling (Figure 1), and suggest a causative role for AR PRB in the 
observed phase specific, DHT-dependent transcriptional networks.
The concept that AR performs unique functions in mitotically active cells was further 
underscored by comparison with previously reported studies of AR cistromes. As shown, 
AR binding analyses herein captured the majority of previously reported sites of AR 
occupancy, wherein cells were arrested in G0 by steroid deprivation prior to DHT 
stimulation (Fig S3)(9, 11). Comparing CCC binding to all post-G0 phases in mitotically 
active cells illustrated high confidence overlap with binding reported by Massie et al., with 
over 80% of ARBSs identified in G0 also exhibiting CCC binding in mitotically active cells. 
Additionally, 60% of AR occupied sites identified by Wang et al. coincided with CCC 
binding, with the reduction in overlapped binding likely due to differences in experimental 
method (ChIP-Chip performed by Wang et al. vs ChIP-Seq performed in the current study, 
Fig 3A, Fig S3). As expected, binding present in G0 and maintained throughout the cell 
cycle is exemplified by occupancy at well-characterized AR targets such as KLK3 (PSA) 
and TMPRSS2 (Fig 3B, panel I, Fig S4). Notably, a significant fraction of CCC AR 
occupied sites detected in mitotically active cells are novel. With respect to CCC binding, 
approximately 70% of the total number of ARBSs were previously unreported (Fig 3A), 
illustrated by AR occupancy seen in Fig 3B, panels I and II. Collectively, these findings 
indicate that AR binding sites found in G0 are sustained throughout the mitotic cell cycle, 
and that AR binding capacity and function are significantly expanded in mitotically active 
cells.
While the fraction of novel CCC binding is substantial, assessment of PRB sites reveals 
further insight into AR function in cycling cells. Over 90% of the PRB events were not 
identified in the G0 enriched datasets (Fig 3C), and represent restricted binding events from 
McNair et al. Page 5
Oncogene. Author manuscript; available in PMC 2017 March 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
each cell cycle phase (Fig 3D). Collectively, these data indicate that while AR function in G0 
cells is largely preserved in cycling cells, AR function in mitotically active cells is greatly 
expanded beyond G0, eliciting patterns that are unique to the post G0-cell cycle as well as 
those that are restricted to specific cell cycle phases. These findings provide the first 
evidence that AR is differentially programmed in cycling cells, and yield significant new 
insight into the mechanisms by which AR likely promotes tumor development and 
progression.
Evidence for Differential AR Cofactor Requirements Throughout the Cell Cycle
The observations that androgen induces distinct transcriptional networks in a cell cycle-
dependent manner (Fig 1), and that AR exhibits an expanded, differential cistrome in 
mitotically active cells (Fig 2) suggests that cell cycle specific signaling is directly regulated 
by AR. To probe the mechanisms and consequence of cell cycle dependent AR regulation, 
motif analyses were performed utilizing PRB events. Enriched motifs were divided into 
three cohorts: constitutively enriched (significantly represented throughout all phases of 
PRB; Fig 4A), differentially enriched (enrichment altered throughout two or more PRB 
phases: Fig 4B), and phase exclusive enriched (motifs present only in single phase indicated; 
Fig 4C, Fig S5, Supplementary Table 2). Additionally, motifs significantly represented using 
CCC binding and previously reported (G0 enriched) datasets were generated for comparison 
to identify cell cycle specific alterations. Interestingly, motifs constitutively enriched in all 
phases of PRB binding were concurrently enriched in CCC and G0 enriched datasets (Fig 
4A). This cohort includes FOXA1, which has been well described as an AR pioneer factor, 
is required for AR activity, and has been shown to contribute to AR reprogramming in tumor 
transformation (Fig 4A) (21, 22). Additionally, the nuclear factor I family member NFIC, 
which interacts with FOXA1 to regulate AR, was enriched in all datasets evaluated (23). The 
AR binding motif was also enriched within CCC binding, in addition to a number of other 
previously described AR interactors including GATA and AP-1, consistent with the overlap 
of CCC motifs and those previously described (21, 24, 25). Interestingly, the AR binding 
motif was enriched in all PRB events except late G1; while lack of enrichment for the AR 
motif in G1 could be due to the decrease in overall binding in this phase (Fig 4B), these data 
suggest potential AR occupancy at non-canonical motifs in late G1. Overall, these data 
suggest that the requirement for pioneer factor function is retained in all phases of cell cycle, 
and that AR generally relies on canonical AR binding motifs across the cell cycle. In 
contrast, novel motif enrichment was observed in AR events that are phase restricted. Over 
80% of the PRB enriched motifs (of 25 total) were shown to be novel when compared to 
those enriched in CCC binding or those identified in previous studies (Fig 4C), suggesting 
that PRB enriched motifs contribute to differential AR function in active cell cycle. This 
cohort of motifs was enriched for factors with known roles in metastasis and DNA damage, 
e.g. ZEB1 and BRCA1 (26, 27), putting forth the concept that differentially enriched, PRB-
specific AR cofactors may not only support cell cycle phase specific AR function, but likely 
contribute to AR-induced tumor phenotypes. Taken together, the high degree of motif 
overlap between previously published binding studies and CCC binding coupled with the 
lack of overlap when comparing the phase-restricted enriched motifs suggest a likely role for 
cell cycle regulated AR cofactors in controlling and facilitating the expanded AR cistrome 
and regulated gene networks in mitotically active cells.
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Expanded AR Function in Mitotically Active Cells Reveals Link to Lethal Tumor 
Phenotypes
To investigate functional consequence of PRB events, a “guilty by association” approach 
was utilized to identify potential targets of phase-restricted AR activity impacted by AR 
binding. Genes with transcriptional start sites (TSS) within 30kb of ARBSs were identified, 
as depicted in Fig 5A, and subsequently compared to genes identified using published 
datasets. As expected, genes associated with CCC binding events overlapped to a high 
degree with those associated with previous reports (88% of Massie dataset validated, 65% of 
Wang dataset validated), replicating the overlap seen using binding alone (Fig S6). 
Importantly, genes associated with PRB nominated a novel AR-regulated gene network, 
further indicating that the function of AR is expanded in mitotically active cells (Fig 5B). 
Genes nominated by proximity to PRB events were then compared to the cohort that 
exhibited differential DHT-induced gene expression (Fig 1B). Strikingly, of the 1098 genes 
identified as showing phase specific AR expression, 319 contained PRB in putative 
regulatory regions (Fig 5C). To discern the biological impact of PRB related, androgen 
induced transcriptional changes, gene ontology (GO) analyses was performed. Due to the 
low number PRB sites in late G1 and late S phases, ontology analyses were restricted to 
events in only early G1, early S, and G2/M phases. Genes associated with PRB events in 
early G1 revealed a significant impact on metabolic processes, whereas early S genes 
unmasked the influence of AR on mitotic progression, including kinetochore assembly, and 
genes with PRB events in G2/M show impact on both metabolic processes and cell cycle 
regulation (Fig 5D). Combined, these data identify critical new transcriptional networks 
likely to be controlled by phase-restricted AR binding, exposing a 319 gene set with both 
phase-restricted binding as well as differential expression. These data suggest for the first 
time that PRB events are linked to androgen-induced phase specific transcriptional responses 
in cycling cells, thus revealing differential AR function throughout the cell cycle.
To explore the biological relevance of the newly identified AR-associated cistrome and 
transcriptome, the 319 gene set (genes exhibiting both PRB and cell cycle regulated gene 
expression) was examined for expression in primary and metastatic PCa in order to identify 
targets likely to have clinical implications. Genes with altered expression in over 10% of 
primary disease were removed, so as to isolate those with changes exclusively after 
metastatic tumor development, nominating 30 prioritized clinically relevant targets (Fig 6A), 
of which 19 were up-regulated and 11 down-regulated. Additionally, a sampling of this 
subset was validated for PRB using an alternate means of synchronization in order to further 
assess cell cycle regulation (Fig 6B top). Targets were identified that exhibited binding 
restricted to early G1 (NRDG1, DEGS1, and CENPF), early S (NREP, MKI67, and 
FOXM1), or G2/M (GRB10, S100A10, RNF44) and validated by ChIP-qPCR in their 
respective phases (Fig 6B middle), thus strengthening these findings. Further, 
synchronization in an additional HTS model system was utilized (VCaP, Fig S7), and ChIP-
qPCR for these sites exhibited PRB in this distinct model system (Fig 6B bottom). 
Functional classification for the prioritized 30 gene set showed association with numerous 
processes associated with lethal malignancies, including metabolism, cell cycle/
proliferation, protein degradation/apoptosis, RNA processing/transcription, and metastasis 
(Fig 6C). A specific emphasis was placed on metastasis, as AR is known to promote 
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metastatic phenotypes (28, 29), but the underlying basis for this function is incompletely 
understood. Within this group, several newly identified genes under likely AR regulation 
have been previously implicated in at least some aspect of PCa biology. For example, 
stathmin-1 (STMN1) is associated with EMT phenotypes (30), whereas NDRG1 has been 
suggested to modulate metastatic development (31), and ARHGAP10 harbors a known role 
in cellular proliferation (32).
The present study provides an unexpected link of AR to modulation of these factors, 
strongly suggestive that AR utilizes these pathways to promote clinical tumor progression. 
Further, semaphorin 4B (SEMA4B), a protein involved in axon extension, was identified in 
this cohort and has been previously implicated in metastasis of non-small cell lung cancer 
(33). Further systematic analysis revealed dihydroceramide desaturase 1 (DEGS1), a 
desaturase invovled in the ceramide synthesis pathway (34), amongst the most clinically 
significant AR-regulated genes. As shown, validation via ChIP-qPCR demonstrated phase-
restricted AR binding to the DEGS1 regulatory region in early G1 (Fig 7A top), with 
maximum gene expression occurring in late S phase (Fig 7A bottom). Intriguingly, this 
phase was where expression of genes involved in EMT co-occurred, a process also linked to 
metastasis. Taken together, prioritization of clinical targets with both PRB and differential 
expression highlighted a 30 gene set over-represented exclusively in metastatic disease, with 
DEGS1 being prioritized due to its potential in promoting metastasis.
Given the likely impact of DEGS1 on PCa tumor behavior, RNAi silencing was utilized to 
ablate DEGS1 protein levels (Fig 7B top). Notably, DEGS1 depletion significantly impeded 
migratory capacity (~50%), suggesting that this newly identified AR-regulated target activity 
promotes pro-metastatic functions (Fig 7B bottom left, with quantification bottom right). 
Interestingly, while bioactive lipids ceramide-1-phosphate (C1P) and sphingosine-1-
phosphate (S1P) have been shown to induce cell proliferation (35, 36), siDEGS1 had no 
effect on Brdu incorporation, suggesting that DEGS1 does not alter proliferative potential in 
this disease type (Fig S8). To further assess the putative role of DEGS1 in PCa progression, 
a large cohort of patients with localized, high risk PCa (n=780) with a median of 11.2 years 
of clinical follow-up was utilized to determine the clinical relevance of DEGS1. As shown, 
univariate analyses identified elevated DEGS1 was strongly associated with reduction in 
freedom from metastasis (Fig 7C, p=3.4e-15) and rapid biochemical recurrence (Fig 7D, p= 
1.9e-06), thus nominating DEGS1 as an AR-regulated predictive marker for metastatic 
progression. Concordantly, DEGS1 was robustly associated with poor prognosis and reduced 
survival, both with regard to PCa-specific survival (Fig 7E, p=7.1e-13) and overall survival 
(Fig 7F, p=1.6e-13). Given the lack of predictive biomarkers to identify aggressive PCa, 
DEGS1 was further examined through multivariate analyses and elevated DEGS1 levels 
showed significant value as an independent predictor of poor outcomes when compared with 
Gleason score and PSA (Fig S9). Taken together, these data show for the first time that 
genes regulated by AR in mitotically active cells are likely drivers of PCa cell progression 
and metastatic events and unveil DEGS1 as an unexpected AR regulated gene of clinical 
relevance (Fig 7G).
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Discussion
Elucidating the mechanisms by which AR induces lethal tumor phenotypes is critical for the 
development of more effective therapeutic strategies to manage PCa. Herein, new and 
unexpected functions of AR were unveiled through profiling AR activity in mitotically 
active cells. Key findings demonstrate that: i) androgen engages a distinct transcriptional 
network in post G0, mitotically active cells; ii) the function of AR in actively cycling cells is 
strikingly expanded during mitotic progression, demonstrating binding events that are 
specific to mitotically active cells and/or restricted to specific cell cycle phase; iii) a distinct 
set of transcription factor motifs are enriched dependent on cell cycle phase; iv) genes 
exhibiting dual cell cycle regulated binding and expression nominate cell cycle specific 
targets with relevance in late stage disease; v) DEGS1 was identified as a cell cycle specific 
AR target gene which alters cell migration in PCa; and vi) DEGS1 independently predicts 
for metastatic development and poor prognosis. Taken together, these data uncover novel 
functions for AR in mitotically active cells, allowing the identification of targets with 
clinical relevance in aggressive disease.
The finding that AR functions differentially in cycling cells when compared to resting cells 
sheds new light on the function of AR activity in PCa, and is consistent with early studies 
suggesting that AR function may be modified by components of the cell cycle machinery 
(37). Herein, differential AR activity in the mitotic cell cycle was demonstrated at a genome-
wide level, with cell cycle phase altering both AR-chromatin interaction as well as 
downstream changes corresponding to cell cycle regulated, DHT induced transcriptional 
output. The newly described AR cistromes in mitotically active cells can be divided into 
binding maintained throughout the cell cycle in cells committed to mitotisis (cell cycle 
common, CCC binding) or binding enriched in a specific cell cycle phase (phase restricted 
binding, PRB). The CCC binding profile notably encompasses the vast majority of 
previously reported AR binding sites, largely identified in DHT-stimulated cells that were 
synchronized in G0 (9, 11), through additional AR binding regions were also identified. 
These binding overlaps include those regulating well-characterized AR target genes (e.g. 
KLK3 and TMPRS22). Such concordance between previously identified AR cistromes and 
the CCC binding profile suggests that AR binding events in DHT stimulated, G0 phase cells 
are largely maintained in actively cycling cells at all phases, and may serve as the “baseline” 
of AR function. However, this subset comprised only ~30% of the CCC cluster, with nearly 
70% of CCC binding events identifying novel AR functions. An even greater expansion of 
AR activity was revealed by the PRB subset (~95% novel binding events not previously 
observed in genome-wide mapping studies enriched in G0 phase), further supporting the idea 
that AR-cell cycle interplay results in novel AR function in cycling cells. PRB-associated 
genes corresponded to differentially enriched processes, with early G1-phase restricted 
binding associated with metabolic processes, early S-phase associated binding with 
chromosomal organization, and G2/M phase restricted binding associated with mitotic 
regulation. These findings are consistent with previous cellular observations suggesting that 
AR promotes G1-S transition (38), and provide some mechanistic basis for this long-
appreciated function for AR. In addition to cell cycle regulated gene networks, new binding 
and transcriptional targets of AR were identified that assist in defining the mechanism(s) by 
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which AR promotes androgen responsiveness (13), metabolism (8, 9), DNA damage (16, 
17), and cell cycle transitions (14, 38). Further, as a subset of prioritized PRB sites were 
validated in multiple model systems, and using a variety of synchronization methods, the 
expansion of the AR cistrome in mitotically active cells is a phenomenon likely to be seen 
across model systems and cell types. The data herein demonstrate that the AR-dependent 
transcriptional networks governing these cancer-associated activities are regulated as a 
consequence of cell cycle position, further underscoring the importance of AR-cell cycle 
interplay in promoting gene expression networks and suggesting implications for tumors 
with alterations in cell cycle regulatory networks.
The discovery that AR activity is modulated as a function of cell cycle position, and that 
these functions of AR appear to be critical for AR-mediated tumor progression, lead to 
provocative hypotheses as to how AR function may be controlled. Data herein demonstrate 
that AR binding events in mitotically active cells are enriched for co-occurrence of 
differential transcription factor motifs (Fig 4B), suggesting that AR may depend on 
differential cooperating factors to elicit cell cycle-specific transcriptional signaling. Known 
motifs of cofactors thought to be requisite for AR activity (e.g. “pioneer factors”, such FOX 
and GATA) (21, 39, 40) associated with AR binding irrespective of cell cycle position, 
consistent with the importance of these factors for AR activity. However, selective 
enrichment of putative transcriptional cooperating factors were observed that have been 
previously linked to malignant phenotypes. Exemplifying this cohort in G1 phase are ZEB1, 
recently shown to be strongly associated with PCa migration and invasion (26, 41) and 
BRCA1, which has a well described role in DNA-repair and transcriptional regulation (42, 
43). Ongoing studies are directed at interrogating the molecular impact of each motif 
enrichment and putative cooperating cofactor activity on AR function, both with regard to 
CCC and PRB events. Such regulation is likely to be complex, as 25 motifs in total were 
exclusively associated with PRB binding in a single phase of cell cycle. Strikingly, PRB-
enriched motifs showed little overlap with CCC-associated motifs, congruent with the 
expanded cistrome seen in mitotically active cells. Notable within this subset is enrichment 
of CTCF in early G1-phase, as CTCF is involved in nucleosome positioning and 
chromosome remodeling (44). CTCF was previously shown to be associated with AR 
binding (45), but this interaction was contingent upon loss of FOXA1 and subsequent 
expansion of AR cistrome; thus, the present data bring forth new understanding of CTCF-
AR interplay. Additionally, the c-myc motif was exclusively enriched in early G1; this motif 
was shown to be enriched in AR binding in clinical CRPC samples (46) and is known to be 
important for PCa survival, up-regulated in PCa, and associated with aggressive disease (47–
50). As AR and c-myc are also known to regulate similar metabolic pathways (51), and have 
been seen to co-regulate target genes (52), the phase specific enrichment provides the 
context to determine how these two major transcriptional effectors of cancer progression act 
in concert to promote disease progression. Overall, these analyses implicate cell cycle 
specific transcriptional regulators as cooperating with AR to promote disease progression, 
and provide the molecular basis for further delineation of cell cycle specific AR function.
Complementing these findings, multiple components of the cell cycle machinery have been 
shown to directly interact with and influence AR activity, and may also contribute to cell 
cycle specific AR function. The early G1 kinase CDK6 enhances AR activity in reporter 
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assays (53), and the CDK4/6 catalytic subunit Cyclin D1 binds and modulates AR activity in 
a target-selective manner (54–56). Notably, a highly oncogenic variant of Cyclin D1 
associated with advanced disease induces mis-regulation of AR and directs expression of 
gene networks promoting metastatic phenotypes (57). In late G1, Cyclin E can enhance AR 
transcriptional activity through direct interaction, suggesting an intricate balance between 
these factors may play a role in the cell cycle regulated activity seen in G1 phase (58). 
Additionally, the RB/E2F1 axis, which controls G1-S transition has been shown to regulate 
AR activity. AR expression is directly regulated by E2F1, and RB loss therefore results in 
enhanced AR expression and output (14). Finally, AR activity in G2/M is intricately 
modulated, as CDK1 can inhibit AR activity through phosphorylation on serine 308, and the 
phosphatase Cdc25b enhances AR activity (59, 60). Determining the contribution of these 
factors in controlling cell cycle specific AR activity will be of high priority, given the advent 
of preclinical findings assessing CDK-targeting therapeutics in PCa and trials for clinical 
assessment for CDK4/6 inhibitors. For example, the CDK4/6 inhibitor palbociclib was 
shown to suppress PCa growth in model systems and to selectively cooperate with AR-
directed therapies (61), and clinical evaluation is currently in progress (http://
clinicaltrials.gov, NCT02059213). The present study has defined AR activity in response to 
palbociclib, both with regard to AR binding and downstream transcriptional regulation, and 
will allow for future studies directed at maximizing AR suppression in the presence of 
palbociclib.
The discovery of previously unrecognized AR transcriptional targets that promote tumor 
progression represents a major advance in our understanding of PCa progression. The newly 
identified AR-regulated genes are linked to diverse processes relevant to cancer progression 
including metastasis, RNA processing/transcription, cell cycle/proliferation, metabolism, 
and protein degradation/apoptosis. While each represents a significant advance in 
understating of AR function, the link to metastasis was particularly striking. Several newly 
identified AR regulated genes in this class (STMN1, NDRG1, and ARHGAP10/
ARHGAP21) have been tentatively linked to metastatic progression, but the mechanisms 
governing expression were unknown (30, 31). The Rho/Rac signaling pathway was recently 
identified as a driver in promotion of metastatic phenotypes in PCa, as part of cooperation 
between AR and DNA-repair factors (29). Here, the Rho GTPase-activating protein 
ARHGAP10 was found to undergo cell cycle specific regulation and as such will be of 
further interest to elucidate the extent of the interplay between AR, cell cycle components, 
and DNA damage factors in controlling metastasis. SEMA4B, a protein involved in 
inhibition of axonal extension, was also up-regulated in metastatic disease. While a role for 
SEMA4B in PCa has not yet been described, in models of non-small cell lung cancer 
(NSCLC) it was shown to inhibit proliferation and cell metastasis (33). Finally, findings 
herein identified DEGS1 as a novel, robust predictor of metastatic disease and poor outcome 
in PCa that is regulated by AR. DEGS1 is poorly understood at the molecular level, but is 
known to be involved in ceramide synthesis, and as shown here, promotes cell migratory 
phenotypes in PCa. These findings strengthen and complement preliminary preclinical 
observations in esophageal carcinoma linking DEGS1 to cell migration (34). Analyses 
herein of human tissues demonstrated that DEGS1 upregulation is tightly linked with a 
decrease in freedom from biochemical recurrence, freedom from metastasis, and overall 
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survival, underlying importance as an AR-induced effector of lethal disease phenotypes. 
Strikingly, DEGS1 independently predicted for aggressive disease, on par with currently 
utilized standards (PSA and Gleason score). As Gleason score is currently the strongest 
currently utilized predictor of poor outcome, added biomarkers with the ability to predict for 
disease progression such as DEGS1 are critical. Translational potential is also noted, as a 
recent study examining the use of a sphingosine kinase inhibitor ABC294640 in PCa was 
seen to additionally inhibit DEGS activity, suggesting that drugs specifically targeting 
DEGS1 may be of therapeutic import (62).
Taken together, molecular assessment of AR activity not only reveals differential function 
across the cell cycle and illuminates new understanding of the mechanisms by which AR 
promotes disease progression, but underscore the importance of discerning cancer-
promoting transcription factor function in mitotically active cells. The present findings yield 
critical new insight into AR function and nominate downstream effectors of AR activity as 
potentially impactful therapeutic targets and biomarkers of lethal disease phenotypes.
Experimental Procedures
Cell Cycle Arrest
Cells were plated in hormone replete media 24 hours prior to treatment. Cells were treated 
24 hours prior to harvest with (final concentration): 0.5μM PD-0332991 (early G1 phase 
enrichment), 5μg/mL roscovitine (late G1 phase enrichment), 2μg/mL aphidicolin (early S 
enrichment), 1mM hydroxyurea (late S enrichment), 2μg/mL aphidicolin for 15 hours, 
followed by washout and treatment with 50ng/mL nocodozole for 9 hours (G2/M phase 
enrichment).
Gene Expression Analysis
Cells were arrested as described above and stimulated with 10nM DHT for 3 hours prior to 
harvest. mRNA was processed and transcriptional analyses performed. Details for full gene 
expression analyses are available in supplemental materials and methods.
ChIP-Seq—Cells were arrested as described above, with biological triplicate for each 
condition, and ChIP-Seq performed as previously described(20). Extended details for ChIP-
Seq data analyses are available in the supplemental methods.
RNA Interference—Cells were seeded at equal density in hormone replete conditions. 
Cells were then transfected for 6–8 hours in serum free conditions with either control or 
siDEGS1 according to manufacturer specifications. Cells were maintained for an additional 
72 hours in serum replete media, treated as specified and harvested at indicated time-point. 
Immunoblot analysis was conducted to confirm knockdown at 72 hours post transfection.
Clinical Analyses—Microarray data on radical prostatectomy samples were obtained 
from the Mayo Clinic and profiled using the Affymetrix Human Exon 1.0 ST array as 
described previously (63, 64). Two independent cohorts of patients: Mayo Clinic I (MCI, 
n=545) (63) and Mayo Clinic II (MCII, n=235) (64), were pooled into the MC cohort 
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(N=780) and evaluated. Microarray data was downloaded from the NCBI Gene Expression 
Omnibus (GSE46691, GSE62116)
DEGS1 expression was split into high versus low by comparing the top 1/3 of DEGS1 
expression versus the bottom 2/3 in each cohort. Kaplan Meier curves for freedom from 
biochemical recurrence (BCR), freedom from metastasis, prostate cancer specific survival 
(PCSS), and overall survival (OS), and P-values were generated using the log-rank test. Cox 
regression was used for both univariate and multivariate analyses. In the multivariate 
analysis: age was treated as a continuous variable; PSA was grouped into low (<10), 
intermediate (10–20), and high (>20); Surgical margin status (SMS), seminal vesicle 
invasion (SVI), extracapsular extension (ECE), and lymph node invasion (LNI) were treated 
as binary variables; and Gleason score was grouped into low (<7), intermediate (7), or high 
(8–10). Stratification by cohort was used when performing pooled analysis to account for 
baseline differences between cohorts (65).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 5. 
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Figure 6. 
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Figure 7. 
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